Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia

  • Authors:
    • Qiu‑Lei Xi
    • Bo Zhang
    • Yi Jiang
    • Hai‑Sheng Zhang
    • Qing‑Yang Meng
    • Ying Chen
    • Yu‑Song Han
    • Qiu‑Lin Zhuang
    • Jun Han
    • Hai‑Yu Wang
    • Jing Fang
    • Guo‑Hao Wu
  • View Affiliations

  • Published online on: September 26, 2016     https://doi.org/10.3892/ol.2016.5191
  • Pages: 4013-4020
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer cachexia remains a leading cause of morbidity and mortality worldwide, despite extensive research and clinical trials. The prominent clinical feature of cancer cachexia is the continuous loss of skeletal muscle that cannot be fully reversed by conventional nutritional support, and that leads to progressive functional impairment. The mechanism underlying muscle loss in patients with cachexia is poorly understood. The present study analyzed 21 cancer patients with or without cachexia, and demonstrated that mitofusin‑2 (Mfn2) was downregulated in the rectus abdominis of patients with cachexia, which was associated with body weight loss. In vitro cell experiments indicated that loss of Mfn2 was associated with atrophy of the C2C12 mouse myoblast cell line. Furthermore, in vivo animal experiments demonstrated that cachexia decreased gastrocnemius muscle mass and Mfn2 expression, and overexpression of Mfn2 in gastrocnemius muscle was able to partially attenuate cachexia‑induced gastrocnemius muscle loss. The results of the present study suggested that Mfn2 is involved in cachexia‑induced muscle loss and may serve as a potential target for therapy of cachexia.

References

1 

Fearon KC, Voss AC and Hustead DS: Cancer Cachexia Study Group: Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 83:1345–1350. 2006.PubMed/NCBI

2 

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H and Martignoni ME: Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 12:1193–1201. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 69:491–497. 1980. View Article : Google Scholar : PubMed/NCBI

5 

Donohoe CL, Ryan AM and Reynolds JV: Cancer cachexia: Mechanisms and clinical implications. Gastroenterol Res Pract. 2011:6014342011. View Article : Google Scholar : PubMed/NCBI

6 

Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G and Muscaritoli M: ESPEN: ESPEN guidelines on parenteral nutrition: Non-surgical oncology. Clin Nutr. 28:445–454. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Deans DA, Tan BH, Wigmore SJ, Ross JA, de Beaux AC, Paterson-Brown S and Fearon KC: The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br J Cancer. 100:63–69. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Romanello V, Guadagnin E, Gomes L, Roder I, Sandri C, Petersen Y, Milan G, Masiero E, Del Piccolo P, Foretz M, et al: Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J. 29:1774–1785. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Soriano FX, Liesa M, Bach D, Chan DC, Palacín M and Zorzano A: Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1alpha, estrogen-related receptor-alpha, and mitofusin 2. Diabetes. 55:1783–1791. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Huang P, Galloway CA and Yoon Y: Control of mitochondrial morphology through differential interactions of mitochondrial fusion and fission proteins. PLoS One. 6:e206552011. View Article : Google Scholar : PubMed/NCBI

11 

White JP, Baltgalvis KA, Puppa MJ, Sato S, Baynes JW and Carson JA: Muscle oxidative capacity during IL-6-dependent cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 300:R201–R211. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Shen T, Zheng M, Cao C, Chen C, Tang J, Zhang W, Cheng H, Chen KH and Xiao RP: Mitofusin-2 is a major determinant of oxidative stress-mediated heart muscle cell apoptosis. J Biol Chem. 282:23354–23361. 2007. View Article : Google Scholar : PubMed/NCBI

13 

Song Z, Ghochani M, McCaffery JM, Frey TG and Chan DC: Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol Biol Cell. 20:3525–3532. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Ranieri M, Brajkovic S, Riboldi G, Ronchi D, Rizzo F, Bresolin N, Corti S and Comi GP: Mitochondrial fusion proteins and human diseases. Neurol Res Int. 2013:2938932013. View Article : Google Scholar : PubMed/NCBI

15 

Kluge MA, Fetterman JL and Vita JA: Mitochondria and endothelial function. Circ Res. 112:1171–1188. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Bach D, Naon D, Pich S, Soriano FX, Vega N, Rieusset J, Laville M, Guillet C, Boirie Y, Wallberg-Henriksson H, et al: Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6. Diabetes. 54:2685–2693. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Hernández-Alvarez MI, Thabit H, Burns N, Shah S, Brema I, Hatunic M, Finucane F, Liesa M, Chiellini C, Naon D, et al: Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1{alpha}/Mitofusin-2 regulatory pathway in response to physical activity. Diabetes Care. 33:645–651. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Zhang HS, Chen Y, Fan L, Xi QL, Wu GH, Li XX, Yuan TL, He SQ, Yu Y, Shao ML, Liu Y, et al: The endoplasmic reticulum stress sensor IRE1α in intestinal epithelial cells is essential for protecting against colitis. J Biol Chem. 290:15327–15336. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Xue J, Li X, Jiao S, Wei Y, Wu G and Fang J: Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology. 138:606–615. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Eura Y, Ishihara N, Yokota S and Mihara K: Two mitofusin proteins, mammalian homologues of FZO, with distinct functions are both required for mitochondrial fusion. J Biochem. 134:333–344. 2003. View Article : Google Scholar : PubMed/NCBI

21 

Yaffe D and Saxel O: Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature. 270:725–727. 1977. View Article : Google Scholar : PubMed/NCBI

22 

Reid MB and Li YP: Tumor necrosis factor-alpha and muscle wasting: A cellular perspective. Respir Res. 2:269–272. 2001. View Article : Google Scholar : PubMed/NCBI

23 

De Larichaudy J, Zufferli A, Serra F, Isidori AM, Naro F, Dessalle K, Desgeorges M, Piraud M, Cheillan D, Vidal H, et al: TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. Skelet Muscle. 2:22012. View Article : Google Scholar : PubMed/NCBI

24 

Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC and Spiegelman BM: Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 98:115–124. 1999. View Article : Google Scholar : PubMed/NCBI

25 

Tisdale MJ: Wasting in cancer. J Nutr. 129:(1S Suppl). S243–S246. 1999.

26 

Argilés JM, Busquets S, Stemmler B and López-Soriano FJ: Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Sugioka R, Shimizu S and Tsujimoto Y: Fzo1, A protein involved in mitochondrial fusion, inhibits apoptosis. J Biol Chem. 279:52726–52734. 2004. View Article : Google Scholar : PubMed/NCBI

28 

Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 8:265–269. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2016
Volume 12 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xi, Q., Zhang, B., Jiang, Y., Zhang, H., Meng, Q., Chen, Y. ... Wu, G. (2016). Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncology Letters, 12, 4013-4020. https://doi.org/10.3892/ol.2016.5191
MLA
Xi, Q., Zhang, B., Jiang, Y., Zhang, H., Meng, Q., Chen, Y., Han, Y., Zhuang, Q., Han, J., Wang, H., Fang, J., Wu, G."Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia". Oncology Letters 12.5 (2016): 4013-4020.
Chicago
Xi, Q., Zhang, B., Jiang, Y., Zhang, H., Meng, Q., Chen, Y., Han, Y., Zhuang, Q., Han, J., Wang, H., Fang, J., Wu, G."Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia". Oncology Letters 12, no. 5 (2016): 4013-4020. https://doi.org/10.3892/ol.2016.5191